Literature DB >> 26224509

Prognostic relevance of microsatellite instability in pT3N0M0 colon cancer: a population-based study.

Francesco Iachetta1, Federica Domati2,3, Luca Reggiani-Bonetti1, Valeria Barresi4, Giulia Magnani1, Luigi Marcheselli1, Claudia Cirilli5, Monica Pedroni1.   

Abstract

Although surgery alone represents a curative approach for patients with pT3N0M0 colon cancer, about 15-20% of these patients develop a relapse of disease. Microsatellite instability (MSI) is one of the most important molecular markers in colorectal cancer. The aim of this study was to investigate the prognostic relevance of MSI in all pT3N0M0 tumors recorded in the Cancer Registry of the Province of Modena--(Northern Italy) within the 2002-2006 period in patients who showed a relapse of disease during the 5-year period of follow-up (59 cases). They were compared to 59 controls similar in clinical and pathological features but with good prognosis. None of the subjects received adjuvant chemotherapy. MSI status was tested using BAT25, BAT26, NR24, and CAT25 fluorescent-labeled mononucleotide markers. The overall prevalence of MSI was 12.7% (15 of 118 cases). MSI was detected mainly in mucinous adenocarcinoma (p < 0.003), in high-grade tumors (p < 0.008), in right-sided neoplasms (p < 0.005), and in patients with a better prognosis, though the difference was not statistically significant (11/59 patients -18.6% vs 4/59 patients -6.7%; OR 0.36 CI 95% 0.11-1.15; p = 0.08). However, in multivariate analysis, MSI status becomes the strongest independent factor associated with relapse (OR 0.21, CI 95% 0.06-0.81; p = 0.023), together with mucinous histological type (OR 0.40, CI 90% 0.18-0.92). MSI is a relevant prognostic factor in stage pT3N0M0 colon cancer suitable to discriminate those patients with a high risk of relapse.

Entities:  

Keywords:  Colon cancer; Microsatellite instability; Population based; Stage

Mesh:

Year:  2015        PMID: 26224509     DOI: 10.1007/s11739-015-1285-6

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  28 in total

1.  Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial.

Authors:  D Klingbiel; Z Saridaki; A D Roth; F T Bosman; M Delorenzi; S Tejpar
Journal:  Ann Oncol       Date:  2014-10-30       Impact factor: 32.976

2.  Individual surgeon, pathologist, and other factors affecting lymph node harvest in stage II colon carcinoma. is a minimum of 12 examined lymph nodes sufficient?

Authors:  Luca Stocchi; Victor W Fazio; Ian Lavery; Jeff Hammel
Journal:  Ann Surg Oncol       Date:  2010-09-14       Impact factor: 5.344

3.  Clinicopathologic characteristics of colorectal cancer with microsatellite instability.

Authors:  S Ziadi; F Ksiaa; R Ben Gacem; N Labaied; M Mokni; M Trimeche
Journal:  Pathol Res Pract       Date:  2013-11-07       Impact factor: 3.250

4.  Revised TN categorization for colon cancer based on national survival outcomes data.

Authors:  Leonard L Gunderson; John Milburn Jessup; Daniel J Sargent; Frederick L Greene; Andrew K Stewart
Journal:  J Clin Oncol       Date:  2009-11-30       Impact factor: 44.544

Review 5.  Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis.

Authors:  Gaëtan Des Guetz; Olivier Schischmanoff; Patrick Nicolas; Gérard-Yves Perret; Jean-François Morere; Bernard Uzzan
Journal:  Eur J Cancer       Date:  2009-05-06       Impact factor: 9.162

6.  Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype.

Authors:  Shuji Ogino; Katsuhiko Nosho; Natsumi Irahara; Jeffrey A Meyerhardt; Yoshifumi Baba; Kaori Shima; Jonathan N Glickman; Cristina R Ferrone; Mari Mino-Kenudson; Noriko Tanaka; Glenn Dranoff; Edward L Giovannucci; Charles S Fuchs
Journal:  Clin Cancer Res       Date:  2009-10-13       Impact factor: 12.531

7.  Era of universal testing of microsatellite instability in colorectal cancer.

Authors:  Xuchen Zhang; Jia Li
Journal:  World J Gastrointest Oncol       Date:  2013-02-15

8.  Tumor-infiltrating lymphocytes in colorectal cancers with microsatellite instability are correlated with the number and spectrum of frameshift mutations.

Authors:  David Tougeron; Emilie Fauquembergue; Alexandre Rouquette; Florence Le Pessot; Richard Sesboüé; Michèle Laurent; Pascaline Berthet; Jacques Mauillon; Frédéric Di Fiore; Jean-Christophe Sabourin; Pierre Michel; Mario Tosi; Thierry Frébourg; Jean-Baptiste Latouche
Journal:  Mod Pathol       Date:  2009-06-05       Impact factor: 7.842

9.  Microsatellite instability has a positive prognostic impact on stage II colorectal cancer after complete resection: results from a large, consecutive Norwegian series.

Authors:  M A Merok; T Ahlquist; E C Røyrvik; K F Tufteland; M Hektoen; O H Sjo; T Mala; A Svindland; R A Lothe; A Nesbakken
Journal:  Ann Oncol       Date:  2012-12-12       Impact factor: 32.976

10.  High lymph node yield is related to microsatellite instability in colon cancer.

Authors:  E J Th Belt; E A te Velde; O Krijgsman; R P M Brosens; M Tijssen; H F van Essen; H B A C Stockmann; H Bril; B Carvalho; B Ylstra; H J Bonjer; G A Meijer
Journal:  Ann Surg Oncol       Date:  2011-10-12       Impact factor: 5.344

View more
  2 in total

1.  Microsatellite instability and B-type Raf proto-oncogene mutation in colorectal cancer: Clinicopathological characteristics and effects on survival.

Authors:  Sebnem Batur; Dogu Vuralli Bakkaloglu; Nuray Kepil; Sibel Erdamar
Journal:  Bosn J Basic Med Sci       Date:  2016-11-10       Impact factor: 3.363

Review 2.  Clinical Significance and Prognostic Relevance of Microsatellite Instability in Sporadic Colorectal Cancer Patients.

Authors:  Angelika Copija; Dariusz Waniczek; Andrzej Witkoś; Katarzyna Walkiewicz; Ewa Nowakowska-Zajdel
Journal:  Int J Mol Sci       Date:  2017-01-06       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.